Jury selection kicks off in Musk v. Altman trial

Jury selection kicks off in Musk v. Altman trial


A combination image shows Sam Altman, CEO of OpenAI, during the Asia-Pacific Economic Cooperation (APEC) CEO Summit in San Francisco, California, U.S., on November 16, 2023 and Elon Musk, Chief Executive Officer of SpaceX and Tesla and owner of X, formerly known as Twitter during Viva Technology conference dedicated to innovation and startups at the Porte de Versailles exhibition centre in Paris, France, June 16, 2023.

Carlos Barria | Gonzalo Fuentes | Reuters

Jury selection is beginning in the high-stakes legal battle between longtime friends turned rivals Elon Musk and Sam Altman at a federal courthouse in Oakland, California.

Judge Yvonne Gonzalez Rogers is overseeing the proceedings, starting Monday, between the world’s richest person and the CEO of OpenAI. Nine jurors will be seated and there will be no alternates, according to a March filing. CNBC is in the courtroom for the proceedings. 

Musk, who co-founded OpenAI in 2015, sued the company, Altman and Greg Brockman, OpenAI’s president, in 2024, alleging they reneged on their commitments to keep the artificial intelligence lab a nonprofit and follow its charitable mission. OpenAI has repeatedly dismissed Musk’s lawsuit as “baseless.” Musk left OpenAI’s board in 2018, and five years later started xAI as a rival, merging that company with SpaceX earlier this year.

Musk has sought a number of different remedies over the course of the case, including the removal of Altman and Brockman from their roles at OpenAI. Musk’s lawyers said in January that he should receive up to $134 billion in “wrongful gains,” though he has since asked to funnel those funds back into the OpenAI charity. 

Gonzalez Rogers opted to divide the trial into two parts: a liability phase to decide if any wrongdoing occurred, and a remedies phase to determine the appropriate damages and next steps. The jury will weigh in during the liability phase only, and its verdict will be advisory, which means Gonzalez Rogers will make the final decision in both sections of the trial. 

The liability phase of the trial is expected to last through mid-May. If OpenAI is found to be at fault, Gonzalez Rogers will hear arguments for the remedies phase, which is scheduled to begin on May 18. Gonzales Rogers said on Monday that she expects the liability piece of the case to wrap up by May 21.

Musk alleges in his lawsuit that he was “assiduously manipulated” and “deceived” by OpenAI, Altman and Brockman and their promises to “chart a safer, more open course than profit-driven tech giants.” He has asked the judge to consider unwinding the company’s recent restructuring, which cemented its structure as a nonprofit with a controlling stake in its for-profit business.

Of the 26 claims that Musk asserted in 2024, only two remain: unjust enrichment and breach of charitable trust. Musk’s lawyers dismissed two of the claims, fraud and constructive fraud, ahead of the trial in an effort to “streamline the case,” according to a filing

The trial lands as Musk prepares to take SpaceX public in what’s likely to be a record IPO and as OpenAI gears up for its own expect public offering later this year. The two companies combined are valued at over $2 trillion on the private market.

— CNBC’s Lora Kolodny contributed to this report.

WATCH: Elon Musk and Sam Altman go to court next week — here’s what to expect from the trial

Elon Musk and Sam Altman go to court next week — here's what to expect from the trial
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source

Investors usually ‘sell in May and go away.’ Why that may not work this year
World

Investors usually ‘sell in May and go away.’ Why that may not work this year

“Sell in May and go away?” Some market participants say it could be better to wait and see this year. The old stock market adage speaks to the phenomenon in which the May-through-October stretch has seasonally borne out to be the worst six-month period of returns for stocks. With traders leaving their desks during the […]

Read More
Nvidia, Intel call buyers defy the dip in chip stocks
World

Nvidia, Intel call buyers defy the dip in chip stocks

Semiconductor stocks are on the verge of posting their biggest down day since March 30, as a huge early rally in Qualcomm completely reversed after the opening bell. The VanEck Semiconductor ETF (SMH) is now down about 1%, but call buyers in at least two key chip stocks are looking for further gains. One of […]

Read More
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs
World

Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs

Pharma thinks it’s found the next frontier in preventing heart attacks.  Novartis, Amgen and Eli Lilly are among the drugmakers betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology. All three of the pharmaceutical giants are in late-stage trials to test whether drugs that cut Lp(a) […]

Read More